Phonotactics specifies which combinations of sound units a language permits in particular structural positions. It concerns sequences and their distribution, rather than only the inventory of individual phonemes. A physically pronounceable sequence need not be a usual word pattern in every language.^[ref]

English commonly permits the syllable onset [st], while [tl] is excluded from ordinary native onsets despite containing familiar consonants. A toy computational grammar over sounds p,t,a might allow exactly the CVC forms matching the regular expression [pt]a[pt], generating four possibilities. This stipulated example separates the sound inventory from a rule for combining it. Real descriptions need to distinguish word positions, syllable positions, loanwords and variation, and may represent graded preferences as well as categorical exclusions.

Articulatory phonetics studies how the moving structures of the vocal tract produce speech. Airflow supplies energy; vocal fold vibration can provide a repeating source; the tongue, lips and other articulators shape or interrupt the flow. Producing voice and shaping recognizable speech are related but distinguishable processes.^[ref]

A simple observation compares a sustained “mmm” with a sustained “sss”. Lightly touching the outside of the throat can help detect the vibration accompanying voicing, while a mirror shows the different lip configurations. This is a qualitative demonstration: the external sensation alone does not measure the detailed motion of the vocal folds.

Descriptions of consonants commonly distinguish place of articulation, where a constriction is formed, from manner of articulation, how the airflow is modified. These descriptions explain why changing the tongue or lips can change the recorded sound without changing the source of airflow. Acoustic phonetics measures the resulting signal, while articulation describes its physical production.

Acoustic phonetics studies speech as a physical sound wave. A microphone records a signal related to changing sound pressure; analysis asks how its amplitude, timing and frequency content vary. A waveform displays variation over time, whereas a spectrogram displays the distribution of signal energy across both time and frequency.

For an original comparison, record a sustained vowel followed by a sustained hiss. Inspect each waveform at the same time scale and compare their spectrograms. Approximately repeated vocal cycles can give a harmonic structure, while the hiss provides an example of a noisier excitation. Broad spectral concentrations associated with the vocal tract are formants; they should be distinguished from the fundamental frequency of a repeating source. The spectrogram's analysis-window duration affects which temporal and spectral details are visible.^[ref]

These are measurements of the signal, rather than direct readings of a listener's perceived pitch or a speaker's tongue position. Relating the signal to perception and production requires auditory phonetics and articulatory phonetics.

Auditory phonetics investigates how listeners hear and interpret the physical sounds of speech. The input is an acoustic signal, but the outcome is a perceptual response: identifying a sound, discriminating two recordings or judging their similarity. It connects acoustic phonetics to hearing and to learned phonetic categories.

A simple controlled listening experiment presents pairs of recorded sounds in a randomized order and asks whether they differ. A separate identification task asks which category each recording belongs to. The tasks answer different questions: a listener can detect a physical difference without assigning the recordings to different phonemes. Praat supports forced-choice listening tasks, including same–different and AXB discrimination designs.^[ref]

The sound history presented to a listener can also matter. In Jessica Maye's infant study with collaborators, different exposure distributions along a speech-sound continuum produced different later discrimination patterns. The result concerns the tested exposure and task, rather than a complete account of how a language's sound system develops.^[ref]

A vowel is a speech sound produced with a relatively open vocal tract, allowing its configuration to shape the sound without the complete closure or strong constriction characteristic of many consonants. Vowel height, vowel backness and lip rounding describe major articulatory differences. The vocal tract's acoustic resonances help determine the resulting formants.^[ref]

For example, [i] is a close front unrounded vowel, whereas [u] is close, back and rounded. Moving between them changes the tongue and lips, even if the fundamental frequency of vocal fold vibration is kept approximately constant. This separates vowel quality from pitch.

Many vowels occupy a syllable nucleus, but articulatory and syllabic descriptions answer different questions: a syllabic consonant can occupy that position too. Written vowel letters are also distinct from vowel sounds; the same spelling can correspond to different pronunciations.

A consonant is a speech sound articulated with a closure or constriction that significantly shapes or interrupts airflow. Its physical description typically specifies place of articulation, manner of articulation and voicing. These describe where the articulators act, how the air passes and whether the vocal folds vibrate.^[ref]

The sounds [p] and [b] both involve the lips and a closure, but differ in their usual voicing classification. A sustained [m] also closes the lips, while opening a route through the nose: an oral closure does not imply that all airflow stops. The distinction between a plosive and a nasal consonant therefore depends on airflow paths, not merely the fact that two lips touch.

The category concerns speech sounds, rather than letters: a written symbol's name and its sound in a particular word are different objects of study. A consonant can also function as a syllabic consonant, so a syllable nucleus is not invariably a vowel.

Verified institutional profile: research on bioassay standards for therapeutic monoclonal antibodies and their structure–function relationships. Historical career account records joining NIBSC in 2015. No birth date or expanded personal name inferred.

Primary source: cdn.who.int/media/docs/default-source/biologicals/bs-documents-%28ecbs%29/2017-documents/bs.2017.2309_1st_international_standard_for_rituximab.pdf?download=true&sfvrsn=2911d43b_5

Verified locator: WHO/BS/2017.2309, 2017 primary NIBSC collaborative-study report; cover verifies first author Sandra Prior. Printed pp. 8 and 10–11 describe parameter equivalence, coded duplicate preparations and study-specific bounds; p. 33 distinguishes conventionally assigned first-standard unitage from calibration of replacement standards. Historical report, not asserted as current regulatory acceptance limits.

Primary product labeling hosted by the National Library of Medicine: dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=74bead6e-b746-4134-817f-0c053ef9e451 . Sections 11 and 12.1 describe etanercept as a soluble dimeric p75 TNF-receptor/Fc fusion protein and explain inhibition of TNF binding to cell-surface receptors. Only molecular composition and mechanism are cited; no treatment regimen is supplied.

Primary EPA glossary: www.epa.gov/iris/iris-glossary . Entries Dose-Response Assessment, Dose-Response Relationship and Endpoint distinguish measured response magnitude from incidence or response probability, and require an identified biological endpoint. Used for terminology, not to infer clinical dosing or a substance-specific threshold.

Primary source: www.usp.org/sites/default/files/usp/document/our-work/biologics/app-notes/etanercept-for-bioassays-application-note.pdf

Verified locator: Official USP Biologics application note; descriptive catalog heading. Primary indexed PDF text verified: How and when to use the etanercept bioassays reference standard, Method validation and Figure 2. L929 murine fibroblast neutralization assay, TNF-alpha, cell-viability readout, assay control and establishment of equivalence limits for parallelism. Direct PDF reader returned 403; no uninspected procedural details or publication date asserted.

Primary ICH-E4 guidance hosted by the FDA: www.fda.gov/media/71279/download . PDF title page dates the guideline November 1994; FDA landing page dates its guidance listing July 1996: www.fda.gov/regulatory-information/search-fda-guidance-documents/e4-dose-response-information-support-drug-registration . Sections I.C–E distinguish concentration response, dose titration and time; Section III discusses study designs. Used for scientific design concepts, not present regulatory obligations or individual dose selection.

USP–NF general chapter 1034, publicly available preview, Section 1, Introduction. Biological assays determine potency and assure activity of biological products; analysis is distinguished from design and validation. Only the public introduction is cited here.

Kansas Historical Society, institutional biographical entry, created April 2011 and modified December 2017. Heading and text identify Takeru Higuchi and his pharmaceutical research; the portrait link is explicitly labelled Takeru Higuchi: www.kansashistory.gov/real_people/graphics/higuchi_takeru.jpg .

Kenneth Spencer Research Library, Personal papers of Takeru Higuchi, PP 359; Box 10, Folder 13, dated 1963. Item title explicitly identifies Mechanism of Sustained-Action Medication. Theoretical Analysis of Rate of Release of Solid Drugs Dispersed in Solid Matrices. This institution-held item connects the exact 1963 paper with Takeru Higuchi, rather than inferring an initial expansion from surname alone.

Primary guidance: www.fda.gov/media/70936/download . Food and Drug Administration, Center for Drug Evaluation and Research, August 1997. Appendix A, printed pp. A-1–A-2, describes basket, paddle and flow-through apparatus, medium selection and agitation. The Dissolution Medium subsection states that sink conditions are desirable but not mandatory. Used as a dated technical source, not as a claim about current binding requirements.

Primary paper: pubmed.ncbi.nlm.nih.gov/14088963/ . T. Higuchi, Journal of Pharmaceutical Sciences 52, 1145–1149 (December 1963); DOI doi.org/10.1002/jps.2600521210 . Original scan hosted in USPTO proceedings: ptacts.uspto.gov/ptacts/public-informations/petitions/1519735/download-documents?artifactId=Oa66ferdR3w2b5pS9-xX0Mcec5DHvuJE3_Ze0mytFlVRg2kA16YpxPc . The original abstract distinguishes diffusion in a homogeneous matrix from solvent leaching of a granular matrix and considers planar and spherical geometry. Initial-only byline retained.

Verified author identity: the University of Kansas Kenneth Spencer Research Library lists this exact 1963 paper in Personal papers of Takeru Higuchi, PP 359, Box 10 Folder 13, archives.lib.ku.edu/repositories/3/archival_objects/124437 . Publisher page onlinelibrary.wiley.com/doi/abs/10.1002/jps.2600521210 retains the literal byline T. Higuchi and University of Wisconsin pharmacy affiliation. Person and empty Work canonicalized to Takeru Higuchi; old person and Work IDs retained as adjacent synonyms. Preserve the published initial-only source title/byline.

Publisher abstract: onlinelibrary.wiley.com/doi/abs/10.1002/jps.2600521210 . It explicitly relates the one-dimensional release rates to the earlier ointment-base equation and distinguishes those results from spherical-pellet release, which it says is not first-order. This is the verified abstract locator for the historical context of the Higuchi equation.

Official technical account: www.fda.gov/science-research/licensing-and-collaboration-opportunities/adaptive-perfusion-novel-in-vitro-drug-release-testing-method-complex-drug-products . Technology Summary defines in-vitro release testing and describes pressure-driven tangential-flow filtration as an alternative to rate-limiting passive dialysis-membrane transport. Development Stage identifies in-vitro data and a prototype. The account links the primary 2021 Journal of Controlled Release paper, PMID 33766693.

Primary publication: www.nature.com/articles/263797a0 . DOI doi.org/10.1038/263797a0 . Robert Langer and Judah Folkman, Nature 263, 797–800 (1976). Primary indexed publisher metadata verifies the full bylines and the historical sustained-release topic; PubMed record pubmed.ncbi.nlm.nih.gov/995197/ .